Description: This discussion looks at alternatives companies are considering in the compensation area including levelized commissions. From Record of Society of Actuaries, Vol. 23, No. 1.

Description: The summary provides an overview of the report, written by the Project Oversight Group.

Description: This session discussion is about development of medical cost estimates, differences between indemnity and HMO techniques, relationship of premiums and capitations, HMO organizational structures, experience rating, community rating and community rating by class. From Record of the Society of Actuaries 1987 Vol. 13, No. 1.

Description: View the following report regarding Risk Scoring in Health Insurance: A Primer.

Description: After many years of decline, the individual disability insurance industry is now experiencing double-digit growth in sales and profits. Attendees learn about quantitative and qualitative evidence of opportunities that exist in the individual disability market, along with specific varying product approaches. From the Record of the Society of Actuaries, Volume 29, No. 1, Session 22

Description: List of workshops and sessions from the New York Annual Meeting with no written record. From Record of the Society of Actuaries Vol. 15, No. 3B.

Description: Full version of The Actuary Newsletter Volume 33, Number 6 - June 1999

Description: Table of contents for The Actuary Magazine - December 2004

Description: Many drugs, like the immunologic drugs used to treat inflammatory and oncologic conditions, are FDA-authorized to treat more than one condition. Given different conditions have varying clinical outcomes and costs, it is likely the same drug provides a range of value across multiple conditions. However, such drugs have traditionally had a single list price and corresponding payer net cost. Indication-based pricing and benefit design (IBPBD) is intended to address the variable clinical and economic value for the same drug across multiple treatment indications. As this trend continues to evolve, the determination of drug value by treatment indication will create risks and/or opportunities in pharmacy benefit design, ultimately impacting pharmacy PMPM forecasting and incurred costs. Learn from faculty as they: Provide the business context for IBPBD. Describe varying structural approaches. Discuss the market conditions that can motivate or demotivate payers. Explore operational barriers. Recommend a role for actuaries. To bring the discussion to life, a case study will be reviewed. By attending the session, you will be able to: • Describe the meaning of Indication-Based Drug Pricing and Benefit Design (IDPBD). • Understand the risks and opportunities with IBPBD. • Articulate the advantages and disadvantages of distinguishing the value of a drug by treatment indications.

Description: If you're an actuary who is interested in international business, you'll appreciate the resources available to members of SOA's International section.